TITLE

FDA APPROVES TRINITY'S UNI-GOLD RECOMBIGEN HIV TEST

PUB. DATE
February 2004
SOURCE
Worldwide Biotech;Feb2004, Vol. 16 Issue 2, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on an approval received by Trinity Biotech plc from the U.S. Food and Drug Administration to market its Uni-Gold Recombigentm HIV test in the U.S.
ACCESSION #
12067821

 

Related Articles

  • Troponin I (Tnl) Point-of-Care Test Gains European Approval.  // International Labmate;Feb/Mar2014, Vol. 39 Issue 2, p55 

    The article offers brief information on the Meritas Troponin I (TnI) point-of-care (POC) tests from Trinity Biotech PLC.

  • Troponin I (TnI) Point-of-Care Test Gains European Approval.  // International Labmate;Apr2014, Vol. 39 Issue 3, p46 

    The article offers brief information on the Troponin I (Tri) point-of-care (POC) test and analyzer from Trinity Biotech PLC.

  • Be our test.  // Echo Magazine;1/15/2004, Vol. 15 Issue 9, p56 

    Reports on the plan of Trinity Biotech PLC to market the Uni-Gold Recombigen HIV test in the U.S. in 2004. Cost of the test; Target customers of the company; Rate of accuracy of the test on the negative samples.

  • Trinity to Buy Sigma's Coagulants.  // Chemical Week;7/3/2002, Vol. 164 Issue 27, p73 

    Reports on the acquisition of the coagulants product division of Sigma Aldrich by Trinity Biotech. Revenue generated by the unit for Sigma.

  • New guidelines issued for primary care of people with HIV.  // Public Health Reports;May/Jun94, Vol. 109 Issue 3, p458 

    Focuses on the booklet `Early Evaluation and Management of HIV Infection,' guidelines by the Public Health Service's Agency for Health Care Policy and Research; Recommendations about disclosure of HIV status; Medical evaluation and management.

  • Two studies show high promise in new class of AIDS drugs. Henahan, Sean // Drug Topics;2/5/96, Vol. 140 Issue 3, p48 

    Reports on the discovery of anti-HIV therapy drugs. Background information; CD4 T cell; HIV viral burden; Trials; Implications; Plans and expectations.

  • Study halted due to results.  // Drug Topics;7/21/97, Vol. 141 Issue 14, p7 

    States that as a result of significant differences in the treatment arms, researchers investigating antiretroviral therapy in Human Immunodeficiency Virus-infected children have ceased the research. Reasons for the decision to halt the study.

  • Combination of Fluoxetine and Cognitive Therapy for the Treatment of Major Depression Among People with HIV Infection: A Time-Series Analysis Investigation. Savard, Josee; Laberge, Benoit; Gauthier, Janel G.; Fournier, Jean-Pierre; Bouchard, Stephane; Baril, Jean-Guy; Bergeron, Michel G. // Cognitive Therapy & Research;Feb98, Vol. 22 Issue 1, p21 

    The aim of the present study was to evaluate the efficacy of a combined treatment of fluoxetine and cognitive therapy for the treatment of major depression in HIV-infected patients. Six HIV-seropositive patients with major depression participated in this study using a multiple-baseline...

  • ACUPUNCTURE AGAINST A.I.D.S. IN AFRICA.  // Guidepoints: Acupuncture in Recovery;May2003, p1 

    Reports that Ugandan medical professionals have learned to do acupuncture to treat HIV-positive persons. Training of caregivers; Facilitation of the acu-detox-with-medication group; Principles of Taoism.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics